Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Daburon, Sophie ^a   Devaud, Christel ^a   Costet, Pierre ^b   Morello, Aurore ^a   Garrigue Antar, Laure ^c   Maillasson, Mike ^d   Hargous, Nathalie ^a   Lapaillerie, Delphine ^e   Bonneu, Marc ^e   Dechanet Merville, Julie ^a   Legembre, Patrick ^f   Capone, Myriam ^a   Moreau, Jean François ^a,g   Taupin, Jean Luc ^a,g  

^a CNRS Bordeaux Segalen University   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e Bordeaux Functional Genomic Center   (France)

^f UNIVERSITÉ DE RENNES 1   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; FAS LIGAND LEUKEMIA INHIBITORY FACTOR GP 190 FUSION PROTEIN; HYBRID PROTEIN; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR GP 190; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CHIMERA; CONTROLLED STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOLECULAR SIZE; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; GENETIC VECTORS; HUMANS; JURKAT CELLS; LIGANDS; MICE; NEOPLASMS; ONCOGENE PROTEINS, FUSION; RECEPTORS, OSM-LIF; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

ANIMALIA; MUS;

EID: 84872241667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054000     Document Type: Article

References (35)

1. Bodmer JL, Schneider P, Tschopp J, (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27: 19-26.
2. Krueger A, Fas SC, Baumann S, Krammer PH, (2003) The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 193: 58-69.
3. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809.
4. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, et al. (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777-1783.
5. Mariani SM, Matiba B, Baumler C, Krammer PH, (1995) Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 25: 2303-2307.
6. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S, (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186: 2045-2050.
7. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, et al. (1998) Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213.
8. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, et al. (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23: 1428-1440.
9. Gearing DP, Thut CJ, VandeBos T, Gimpel SD, Delaney PB, et al. (1991) Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. Embo J 10: 2839-2848.
10. Taupin JL, Miossec V, Pitard V, Blanchard F, Daburon S, et al. (1999) Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains. J Biol Chem 274: 14482-14489.
11. Voisin MB, Bitard J, Daburon S, Moreau JF, Taupin JL, (2002) Separate functions for the two modules of the membrane-proximal cytokine binding domain of glycoprotein 190, the leukemia inhibitory factor low affinity receptor, in ligand binding and receptor activation. J Biol Chem 277: 13682-13692.
12. Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, et al. (2006) gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. Biochem Biophys Res Commun 346: 649-657.
13. Boulanger MJ, Garcia KC, (2004) Shared cytokine signaling receptors: structural insights from the gp130 system. Adv Protein Chem 68: 107-146.
14. Legembre P, Moreau P, Daburon S, Moreau JF, Taupin JL, (2002) Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell Death Differ 9: 329-339.
15. Taupin JL, Acres B, Dott K, Schmitt D, Kieny MP, et al. (1993) Immunogenicity of HILDA/LIF either in a soluble or in a membrane anchored form expressed in vivo by recombinant vaccinia viruses. Scand J Immunol 38: 293-301.
16. Kaufman RJ, Davies MV, Wasley LC, Michnick D, (1991) Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res 19: 4485-4490.
17. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, et al. (1991) The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 11: 1980-1987.
18. Tian Q, Taupin J, Elledge S, Robertson M, Anderson P, (1995) Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 182: 865-874.
19. Messier TL, Pittman DD, Long GL, Kaufman RJ, Church WR, (1991) Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X. Gene. 99: 291-294.
20. Nagata S, Onda M, Numata Y, Santora K, Beers R, et al. (2002) Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 8: 2345-2355.
21. Uphoff CC, Drexler HG, (2005) Detection of mycoplasma contaminations. Methods Mol Biol 290: 13-23.
22. Chen TR, (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255-262.
23. Taupin JL, Gualde N, Moreau JF, (1997) A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor. Cytokine 9: 112-118.
24. Beneteau M, Daburon S, Moreau JF, Taupin JL, Legembre P, (2007) Dominant-negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res 67: 108-115.
25. Schagger H, (2002) Respiratory chain supercomplexes of mitochondria and bacteria. Biochim Biophys Acta 1555: 154-159.
26. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, et al. (1998) Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 103: 335-342.
27. Legembre P, Beneteau M, Daburon S, Moreau JF, Taupin JL, (2003) Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J Immunol 171: 5659-5662.
28. Chodorge M, Zuger S, Stirnimann C, Briand C, Jermutus L, et al. (2012) A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ.
29. Chida Y, Sudo N, Takaki A, Kubo C, (2005) The hepatic sympathetic nerve plays a critical role in preventing Fas induced liver injury in mice. Gut 54: 994-1002.
30. Descamps D, Vigant F, Esselin S, Connault E, Opolon P, et al. (2006) Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis. Hepatology 44: 399-409.
31. Krautwald S, Ziegler E, Tiede K, Pust R, Kunzendorf U, (2004) Transduction of the TAT-FLIP fusion protein results in transient resistance to Fas-induced apoptosis in vivo. J Biol Chem 279: 44005-44011.
32. Song E, Lee SK, Wang J, Ince N, Ouyang N, et al. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351.
33. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, et al. (2003) Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 171: 562-568.
34. Matsuda Y, Toda M, Kato T, Kuribayashi K, Kakimi K, (2006) Fulminant liver failure triggered by therapeutic antibody treatment in a mouse model. Int J Oncol 29: 1119-1125.
35. Shiraishi T, Suzuyama K, Okamoto H, Mineta T, Tabuchi K, et al. (2004) Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem Biophys Res Commun 322: 197-202.